Scienion said this week that it will provide protein microarray batches of more than 1,000 arrays to Protagen for that company's clinical validation studies of its protein biomarker panels.
According to Protagen chief scientific officer Peter Schulz-Knappe, the microarray batches will be used in "multicenter, clinical validation studies" of the company's protein biomarker panels for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.
Additionally, the two Dortmund, Germany-based firms will collaborate under a strategic partnership to evaluate new platforms for multiplex analytics and develop new techniques that they will carry through jointly to the proof-of-concept stage.
"Scienion's sciFlexArrayer technology allows the manufacturing of protein microarray batches each with more than 3,500 single proteins in highest quality and reproducibility," Schulz-Knappe said in a statement. "Thereby, we can realize the needed consistency in quality and properties throughout three stages: from spot to spot, from array to array, and from batch to batch."
Financial and other terms of the agreement were not disclosed.